{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:22:54Z","timestamp":1784917374206,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejpb.2023.06.013","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T04:20:14Z","timestamp":1687666814000},"page":"189-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Creation of a ready-to-use brexpiprazole suspension and the inflammation-mediated pharmacokinetics by intramuscular administration"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-2764","authenticated-orcid":false,"given":"Junji","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0606-5513","authenticated-orcid":false,"given":"Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.06.013_b0005","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2023.06.013_b0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","author":"Lobo","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejpb.2023.06.013_b0015","article-title":"Dopamine receptor partial agonists: do they differ in their clinical efficacy?","volume":"12","author":"Mohr","year":"2021","journal-title":"Front. Psych."},{"key":"10.1016\/j.ejpb.2023.06.013_b0020","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1176\/appi.ajp.2019.19090952","article-title":"Developing innovative and novel treatment strategies","volume":"176","author":"Kalin","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejpb.2023.06.013_b0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11920-021-01298-w","article-title":"New antipsychotic medications in the last decade","volume":"23","author":"Pahwa","year":"2021","journal-title":"Curr. Psychiatry Rep."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.013_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S1092852913001016","article-title":"Long-acting injectable antipsychotics: shall the last be first?","volume":"19","author":"Stahl","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejpb.2023.06.013_b0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.013_b0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1017\/S1092852921000249","article-title":"Long-acting injectable antipsychotics: what, when, and how","volume":"26","author":"Citrome","year":"2021","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejpb.2023.06.013_b0045","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14737175.2013.811984","article-title":"New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia","volume":"13","author":"Citrome","year":"2013","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejpb.2023.06.013_b0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40263-018-0508-6","article-title":"Long-acting injectable second-generation antipsychotics: an update and comparison between agents","volume":"32","author":"Jann","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejpb.2023.06.013_b0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12272-013-0105-7","article-title":"Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia","volume":"36","author":"Park","year":"2013","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.06.013_b0060","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2023.06.013_b0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.114.213819","article-title":"Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2023.06.013_b0070","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/00498254.2021.1890275","article-title":"Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human","volume":"51","author":"Sasabe","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejpb.2023.06.013_b0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/npr2.12180","article-title":"Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole","volume":"41","author":"Kikuchi","year":"2021","journal-title":"Neuropsychopharmacol. Rep."},{"key":"10.1016\/j.ejpb.2023.06.013_b0080","unstructured":"H. Yamashita, Y. Sakurai, M. Miyamoto, Y. Nakamura, H. Kuroda, T. Minowa, Piperazine-substituted benzothiophene derivatives as antipsychotic agents, in, Google Patents, 2019."},{"key":"10.1016\/j.ejpb.2023.06.013_b0085","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/chromsci\/bmy045","article-title":"A validated quantification method for brexpiprazole in dog plasma","volume":"56","author":"Zou","year":"2018","journal-title":"J. Chromatogr. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2023.06.013_b0090","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/mp500070m","article-title":"Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics","volume":"11","author":"Remenar","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.06.013_b0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2020.05.022","article-title":"Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs","volume":"324","author":"Surve","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.06.013_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106220","article-title":"Long-acting drugs and formulations for the treatment and prevention of HIV infection","volume":"57","author":"Flexner","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejpb.2023.06.013_b0105","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","article-title":"A year-long extended release nanoformulated cabotegravir prodrug","volume":"19","author":"Kulkarni","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ejpb.2023.06.013_b0110","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/s41467-022-30902-7","article-title":"Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation","volume":"13","author":"Deodhar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2023.06.013_b0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/11203810-000000000-00000","article-title":"Intramuscular paliperidone palmitate","volume":"24","author":"Hoy","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejpb.2023.06.013_b0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejpb.2018.06.024","article-title":"Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery","volume":"130","author":"Ho","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.06.013_b0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2019.09.001","article-title":"Creation of a long-acting rilpivirine prodrug nanoformulation","volume":"311","author":"Hilaire","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.06.013_b0130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0000000000000691","article-title":"Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia","volume":"37","author":"Hard","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejpb.2023.06.013_b0135","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1038\/s41467-021-25690-5","article-title":"Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles","volume":"12","author":"Cobb","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ejpb.2023.06.013_b0140","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1021\/acs.cgd.7b01747","article-title":"Structural diversity of brexpiprazole and related analogues: impact on solubility and drug delivery","volume":"18","author":"Zeidan","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2023.06.013_b0145","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.addr.2007.05.013","article-title":"Prodrug strategies to overcome poor water solubility","volume":"59","author":"Stella","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.013_b0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s13346-022-01223-5","article-title":"An expanding horizon of complex injectable products: development and regulatory considerations","volume":"13","author":"Panchal","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2023.06.013_b0155","first-page":"222","article-title":"Invega Trinza: the first four-times-a-year, long-acting injectable antipsychotic agent","volume":"41","author":"Daghistani","year":"2016","journal-title":"Pharmacy and Therapeutics"},{"key":"10.1016\/j.ejpb.2023.06.013_b0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1017\/S1092852919000816","article-title":"Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia","volume":"25","author":"Jain","year":"2020","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejpb.2023.06.013_b0165","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/jps.24014","article-title":"Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats","volume":"103","author":"Darville","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.06.013_b0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2016.03.041","article-title":"The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension","volume":"230","author":"Darville","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.06.013_b0175","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1021\/acs.molpharmaceut.2c00348","article-title":"Microcrystals of Ketal-Linked Paliperidone prodrugs for long-acting antipsychotics","volume":"19","author":"Xu","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.06.013_b0180","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s11095-014-1308-4","article-title":"Long-acting atypical antipsychotics: characterization of the local tissue response","volume":"31","author":"Paquette","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.06.013_b0185","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2021.06.023","article-title":"Evaluating parameters affecting drug fate at the intramuscular injection site","volume":"336","author":"McCartan","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.06.013_b0190","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1017\/S1092852920002072","article-title":"Aripiprazole lauroxil dosing regimens: understanding dosage strengths and injection intervals","volume":"27","author":"Sommi","year":"2022","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ejpb.2023.06.013_b0195","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/jps.23258","article-title":"Species difference of esterase expression and hydrolase activity in plasma","volume":"101","author":"Bahar","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.06.013_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmbbm.2019.103504","article-title":"On the characterization of interstitial fluid flow in the skeletal muscle endomysium","volume":"102","author":"Wang","year":"2020","journal-title":"J. Mech. Behav. Biomed. Mater."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:53:31Z","timestamp":1760547211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123001662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":40,"alternative-id":["S0939641123001662"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.06.013","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Creation of a ready-to-use brexpiprazole suspension and the inflammation-mediated pharmacokinetics by intramuscular administration","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}